Information Provided By:
Fly News Breaks for May 10, 2019
May 10, 2019 | 11:16 EDT
H.C. Wainwright analyst Joseph Pantginis raised his price target for Pieris Pharmaceuticals (PIRS) to $7 from $5 and maintained a Buy rating following the company's Q1 results. In a research note to investors, Pantginis says he believes Pieris' lead respiratory program, PRS-060, which is partnered with AstraZeneca (AZN) should see a significant boost in visibility and potential value this year starting later this month at the American Thoracic Society, and feels that the partnership and options for Pieris are the key to long-term value.
News For PIRS;AZN From the Last 2 Days
Jul 20, 2019 | 07:27 EDT
Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump and his administration with this weekly recap compiled by The Fly: 1. PENTAGON'S CLOUD-COMPUTING CONTRACT:... To see the rest of the story go to See Story Here